Independent support for the Foxy-5 program in prostate cancer

Press release from Companies

Published: 2014-06-13 12:45:17

WntResearch AB: Independent support for the Foxy-5 program in prostate cancer

WntResearch AB today announces that a very interesting meeting abstract was published in “Bone abstracts” under the head line: “WNT5A has anti-prostate cancer effects and protects against bone metastases” (please follow link below) by scientist working in Dresden, Germany reporting from the "European Calcified Tissue Society Congress" held Prague, Czech Republic in May 2014. The results in this study confirms the previous results published by professor Tommy Andersson and professor Anders Bjartell, Lund University, Sweden that Wnt-5a expression in the primary prostate cancer tissue predicts good prognosis. As important, this abstract describes that prostate cancer cell lines expressing Wnt-5a exhibit reduced growth and are less metastatic than prostate cancer cell lines not expressing Wnt-5a. These independent scientists draw the conclusion that "WNT5A may act as a tumor suppressor in prostate cancer and suggest that “Wnt-5a may emerge as a novel therapeutic target for prostate cancer and bone metastases".

CEO Nils Brünner comments: “The publication “WNT5A has anti-prostate cancer effects and protects against bone metastases” from a German independent research group confirms and expands the basis for using Foxy-5 in the treatment of patients with prostate cancer that has a low expression of the Wnt-5a protein. These exciting results further strengthens the concept of Foxy-5 being a potentially important novel drug for prostate cancer patients.” Please visit: www.bone-abstracts.org/ba/0003/ba0003OC5.4.htm For further information please contact: Nils Brünner, CEO E-mail: nbr@wntresearch.com Telephone: +45 2614 4708 About Foxy-5 Foxy-5 is an anti-metastatic drug candidate in clinical Phase 1. Foxy-5 represents a new concept (first-in-class) in the treatment of cancer. The drug candidate aims directly at the metastatic process. The spread of the tumor is the most common reason of death for cancer patients. Foxy-5 is one of the first anti-metastatic drug candidates to be investigated in the clinical setting. Foxy-5 offers a potential shift in the anticancer treatment paradigm in the treatment of many large cancer indications including breast-, colon, and prostate cancer. About WntResearch WntResearch (WNT.ST) is a public company listed at AktieTorget. WntResearch is developing novel anti-metastatic therapies for the treatment of cancer patients with metastasis. The company’s lead product Foxy-5 is in phase 1 and Box-5 is in pre-clinical phase. The company is focusing on Foxy-5.